Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06319248 · ClinicalTrials.gov registry record · Phase 2
MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial
A Phase 2 study of Sepsis and Low Blood Pressure, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
- 1
- Study location
NCT06319248 is a Phase 2 study of Sepsis and Low Blood Pressure that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 308 participants, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06319248, a Phase 2 study of Sepsis and Low Blood Pressure, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine if early administration of Midodrine can improve outcomes by maintaining a higher mean blood pressure off of intravenous medications. Researchers want to see if Midodrine can help people with sepsis need fewer vasopressors, which could mean shorter hospital stays, less time with uncomfortable tubes, and a smoother recovery overall.
Conditions Studied
Interventions
- OTHER Standard of Care
- DRUG Midodrine
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2029-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06319248
The ClinicalTrials.gov registry entry for NCT06319248 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT06319248 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06319248 about?
NCT06319248 is a clinical study titled "MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial". This study is being done to determine if early administration of Midodrine can improve outcomes by maintaining a higher mean blood pressure off of intravenous medications. Researchers want to see if Midodrine can help people with sepsis need fewer vasopressors, which could mean shorter hospital stay...
What is the current status of trial NCT06319248?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2024-05-14. Estimated completion is 2029-07-30.
What conditions does trial NCT06319248 study?
This clinical trial studies the following conditions: Sepsis, Low Blood Pressure.
What interventions are being tested in trial NCT06319248?
The interventions under investigation include: Standard of Care (OTHER), Midodrine (DRUG).
Who is sponsoring clinical trial NCT06319248?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06319248 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
RECRUITING · Phase 2
-
An Acupuncture Study for People At High Risk for Sepsis
RECRUITING · Phase 2
-
Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection
COMPLETED · Phase 2
-
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
COMPLETED · Phase 2
-
Inulin for Infections in the Intensive Care Unit
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.